Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UKGANI, Ray; GIOVANNONI, Gavin; BATES, David et al.PharmacoEconomics (Auckland). 2008, Vol 26, Num 7, pp 617-627, issn 1170-7690, 11 p.Article

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillationKANSAL, Anuraag R; SORENSEN, Sonja V; GANI, Ray et al.Heart (London 1996). 2012, Vol 98, Num 7, pp 573-578, issn 1355-6037, 6 p.Article

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and BelgiumHETTLE, Robert; WOUTERS, Hanne; AYRES, Jon et al.Respiratory medicine. 2012, Vol 106, Num 12, pp 1722-1733, issn 0954-6111, 12 p.Article